6[1]Sawada N, Ishikawa T, Fukase Y, et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine efiicacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res, 1998, 4 (4) :1013
7[2]Tsuchida Y, Therasse P. Response evaluation criteria in solid tumors (RECIST): New guidelines. Med Pediatr Oncol, 2001,37 (1) :1
8[4]Jones S, Erban J, Overmoyer B, et al. Randomized trial comparing docetaxel and paclitaxel in patients with metastatic breast cancer. The 26th Annual SanAntonio Breast Cancer Symposium,2003 (abstract 10)
9[6]Schuller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration in colorectal cancer patients. Cancer Chemother Pharmacol, 2000, 45(4):291
10[8]George W Sledge, Donna Neuberg, Patricia Bemardo, et al.Phase Ⅲ trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front- line chemotherapy for metastatic breast cancer: An Intergroup Trial (El193). J Clin Oncol, 2003, 21 (4) :588
